Advertisement

Advertisement

Gastrointestinal Cancer
Gastroesophageal Cancer

Perioperative or Postoperative Oxaliplatin/S-1 vs Postoperative Oxaliplatin/Capecitabine for Locally Advanced Gastric Cancer

In the Chinese phase III RESOLVE trial reported in The Lancet Oncology, Zhang et al found that perioperative S-1/oxaliplatin was superior to—and adjuvant S-1/oxaliplatin was noninferior to—adjuvant capecitabine/oxaliplatin in terms of disease-free survival in patients undergoing D2 gastrectomy for...

Gastrointestinal Cancer
Immunotherapy

Atezolizumab Plus Bevacizumab in Malignant Peritoneal Mesothelioma

A phase II study published by Kanwal Raghav, MBBS, MD, and colleagues in Cancer Discovery found that combination treatment with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab was well tolerated and resulted in a 40% objective response rate in patients with advanced malignant...

Gastrointestinal Cancer

KIT Inhibitor Combination Shows Efficacy in Refractory GIST

In a phase Ib/IIa trial reported in JAMA Oncology, Wagner et al found that the combination of a type I KIT inhibitor, PLX9486, with the type II inhibitor sunitinib produced clinical benefit and improved progression-free survival rates in patients with refractory gastrointestinal stromal tumors...

Gastrointestinal Cancer
Issues in Oncology

Effect of Obesity on Receipt of Chemotherapy in Patients With Colorectal Cancer

Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy relative to their body surface area than nonobese patients, according to results from a large meta-analysis reported by Slawinski et al at the ESMO World Congress on Gastrointestinal Cancer 2021 (Abstract...

Gastrointestinal Cancer
Immunotherapy

DESTINY-Gastric01 Exploratory Biomarker Analysis Examines Efficacy of Trastuzumab Deruxtecan-nxki Among Patients With HER2-Positive and HER2-Low Gastric Cancer

Trastuzumab deruxtecan-nxki demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer, according to findings from a post hoc exploratory biomarker analysis presented by Kohei Shitara, MD, and colleagues at the ESMO World ...

Gastroesophageal Cancer
Gastrointestinal Cancer

International Esodata Study Group Model for Predicting 90-Day Mortality After Esophagectomy

In a retrospective analysis reported by researchers from the International Esodata Study Group (IESG) in JAMA Surgery, D’Journo et al developed a model for predicting risk of 90-day mortality following esophagectomy for patients with esophageal or gastroesophageal junction cancer. As stated by the...

Gastrointestinal Cancer

Addition of Neoadjuvant Chemotherapy to Surgery and Adjuvant S-1 in Locally Advanced Gastric Cancer

In the Korean phase III PRODIGY trial reported in the Journal of Clinical Oncology, Yoon-Koo Kang, MD, and colleagues found that the addition of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) to D2 gastrectomy followed by adjuvant S-1 was associated with improved progression-free survival in...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Addition of First-Line Nivolumab to Chemotherapy in Advanced Gastric Cancers: CheckMate 649

As reported in The Lancet by Yelena Y. Janjigian, MD, and colleagues, the phase III CheckMate 649 trial has shown that the addition of first-line nivolumab to chemotherapy resulted in improved overall and progression-free survival among patients with advanced HER2-negative gastric, gastroesophageal ...

Gastrointestinal Cancer

Adjuvant Imatinib Therapy Offers Survival Benefit in Patients With Resected GIST, but Team Effort May Be Needed to Reduce Early Discontinuation Rates

Clinical trial data show that adjuvant imatinib improves recurrence-free survival as well as overall survival, when administered for at least 3 years, among patients who undergo a macroscopically complete resection of a primary gastrointestinal stromal tumor (GIST), Chandrajit P. Raut, MD, MSc,...

Gastrointestinal Cancer
Immunotherapy

Fam-trastuzumab Deruxtecan-nxki for Trastuzumab-Pretreated Advanced HER2-Positive Gastric Adenocarcinoma

On January 15, 2021, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was approved for treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma who have received a prior trastuzumab-based regimen.1,2 Supporting Efficacy Data...

Issues in Oncology
Immunotherapy
Breast Cancer
Bladder Cancer
Gastrointestinal Cancer
Hepatobiliary Cancer

FDA ODAC Meeting Focuses on ‘Dangling’ Accelerated Approvals of Anti–PD-1/PD-L1 Antibodies

In a perspective in The New England Journal of Medicine, Julia A. Beaver, MD, and Richard Pazdur, MD, of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE), discussed issues surrounding “dangling” accelerated approvals of anti–PD-1/PD-L1 antibodies—ie, approvals for...

Gastrointestinal Cancer
Genomics/Genetics

Avapritinib vs Other Tyrosine Kinase Inhibitors for PDGFRA D842V–Mutated Gastrointestinal Stromal Tumors

Data from a study published by Margaret von Mehren, MD, and colleagues in BMC Cancer showed that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V...

Gastrointestinal Cancer
Pancreatic Cancer
Neuroendocrine Tumors

Lenvatinib for Previously Treated Advanced Pancreatic and Gastrointestinal Neuroendocrine Tumors

In a phase II trial (TALENT; GETNE1509) reported in the Journal of Clinical Oncology, Jaume Capdevila, MD, and colleagues found that lenvatinib produced durable responses in patients with previously treated advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors. Study Details In the...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer

On May 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...

Gastrointestinal Cancer
Gastroesophageal Cancer
Hepatobiliary Cancer
Immunotherapy

More From the FDA ODAC: Votes on Agents for Pretreated Hepatocellular Carcinoma and Gastric Cancer

More news has emerged from this week’s meeting of the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). The group voted 8 to 0 in favor of continuing the accelerated approval for pembrolizumab in sorafenib-pretreated patients with hepatocellular carcinoma; 6 to 2...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

FDA Pipeline: Bemarituzumab Granted Breakthrough Therapy Designation for FGFR2b-Overexpressing, HER2-Negative Gastric Cancer

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b)-overexpressing and HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma

Today, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. CheckMate 649 The efficacy of the...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Adjuvant Nivolumab for Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy: CheckMate 577

As reported in The New England Journal of Medicine by Ronan J. Kelly, MBBCh, MBA, and colleagues, an interim analysis of the phase III CheckMate 577 trial has shown a significant improvement in disease-free survival with adjuvant nivolumab vs placebo in patients with resected esophageal or...

Gastrointestinal Cancer

Anesthesiologist Volume and Adverse Short-Term Outcomes After Complex Surgery for Gastrointestinal Cancer

In a Canadian study reported in JAMA Surgery, Hallet et al found that higher anesthesiologist volume was associated with reduced risk of short-term adverse postoperative outcomes in patients undergoing complex surgery for gastrointestinal cancer. Study Details The population-based cohort study...

solid tumors
gastrointestinal cancer
genomics/genetics

Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a variety of RET fusion–positive cancers, including treatment-refractory gastrointestinal malignancies. This analysis highlights the need for genomic profiling to identify actionable oncogenic drivers.

colorectal cancer
gastrointestinal cancer

Heinz-Josef Lenz, MD, and Axel Grothey, MD, on Liquid Biopsies for Colorectal and Other GI Cancers

Gastrointestinal Cancer

Discrepancies in HER2 Assessment for Metastatic Gastric Cancer

In the German VARIANZ study reported in the Journal of Clinical Oncology, Haffner et al found discrepancies between findings in central and local testing of HER2 status in patients with metastatic gastric cancer. In addition, survival outcomes among patients treated with trastuzumab were better...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Pembrolizumab in Microsatellite Instability–High Advanced Gastric or Gastroesophageal Junction Cancer

In an analysis reported in JAMA Oncology, Joseph Chao, MD, and colleagues found improved outcomes with pembrolizumab treatment in patients with microsatellite instability–high (MSI-H) advanced gastric or gastroesophageal junction cancer, irrespective of line of treatment. The findings suggest that...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Mary F. Mulcahy, MD, and Crystal S. Denlinger, MD, on NCCN Guidelines Updates: Gastric and Esophageal Cancers

Crystal S. Denlinger, MD, of Fox Chase Cancer Center, and Mary F. Mulcahy, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss biomarkers for determining treatment; immune checkpoint inhibitors; when to employ such treatments as platinum/fluoropyrimidine and fam-trastuzumab deruxtecan-nxki; and other second- or later-line therapies such as paclitaxel, ramucirumab, irinotecan-based regimens, and trifluridine/tipiracil.

Gastrointestinal Cancer
Health-Care Policy

Medicaid Expansion Is Associated With Earlier Diagnosis of Gastric Cancer, Improved Survival

Medicaid expansion caused a decrease in uninsured patients and led to an earlier diagnosis of gastric cancer with an associated increase in 1-year survival, according to research presented by Zhu et al at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Following Neoadjuvant Chemoradiation Therapy

Adjuvant nivolumab is the first therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival in patients with resected esophageal and gastroesophageal junction cancer, according to research presented by Guillaume Piessen, MD, PhD, and colleagues at...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Expert Point of View: Rutika Mehta, MD, MPH

The FIGHT study’s invited discussant, Rutika Mehta, MD, MPH, a gastrointestinal oncologist at Moffitt Cancer Center, Tampa, Florida, noted the emergence of new biomarkers and their targeted agents in HER2-negative gastric or gastroesophageal junction cancer. Two important ones are FGFR2b—now...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Targeting FGFR2b With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer

Gastric cancer appears to have a new druggable target: fibroblast growth factor receptor 2b (FGFR2b). Targeting FGFR2b with bemarituzumab plus chemotherapy led to clinically meaningful and statistically significant improvements in progression-free survival, overall survival, and response rate in...

Gastrointestinal Cancer
Immunotherapy

Expert Point of View: Elizabeth Smyth, MD

The overall survival benefit for PD-L1 CPS ≥ 5 tumors in CheckMate 649 is a game-changer. An oxaliplatin doublet plus chemotherapy should become a standard of care for these patients,” according to Elizabeth Smyth, MD, an oncology consultant at Cambridge University Hospital NHS Foundation Trust in...

Gastrointestinal Cancer
Immunotherapy

Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?

As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...

Gastrointestinal Cancer

ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers

Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...

Gastrointestinal Cancer

IMbrave150 Trial: Atezolizumab Plus Bevacizumab Improves Survival in Unresectable Hepatocellular Carcinoma

As reported in The New England Journal of Medicine by Richard S. Finn, MD, of Jonsson Comprehensive Cancer Center, Geffen School of Medicine at the University of California, Los Angeles, and colleagues, the phase III IMbrave150 trial has shown that anti–PD-L1 plus anti-VEGF therapy with...

Gastrointestinal Cancer

Novel Therapies and New Indications for Use in the Treatment of Gastrointestinal Cancers

The past year has witnessed the U.S. Food and Drug Administration (FDA) approval of a number of novel drugs and new indications for treating patients with gastrointestinal malignancies. A summary of these approvals is provided herein. Nivolumab plus ipilimumab: On March 10, 2020, the FDA granted...

Gastrointestinal Cancer

Two Studies Validate Neoadjuvant Chemotherapy With Short-Course Radiotherapy or Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer

In the treatment of resectable, locally advanced rectal cancer, researchers are trying to identify the most effective chemotherapy regimens, the best radiotherapy approaches, and the optimal sequence of these modalities. Two phase III trials presented during the ASCO20 Virtual Scientific Program...

Gastrointestinal Cancer

Gastrointestinal Oncology Highlights 2020–2021 Almanac

Cancers of the digestive tract account for 338,090 new cases and 169,280 deaths annually in the United States. Although the overall mortality from these cancers is decreasing, this has been countered by an increase in the incidence of colorectal cancer in young adults. The rising incidence and poor ...

Gastrointestinal Cancer

Sara Schottenstein Foundation, Dedicated to Gastric Cancer, Announces Launch

A science-focused organization dedicated to ending gastric cancer, the Sara Schottenstein Foundation recently announced its launch and its new website, http://www.saraschottensteinfoundation.org. Founded by Jeff Schottenstein, MBA, a wealth management professional in San Francisco, the Sara...

Gastrointestinal Cancer

Outcomes of Complex Gastrointestinal Cancer Surgeries at Ranked vs Nonranked Hospitals

Patients whose procedures for gastrointestinal malignancies were performed by a surgical team at a hospital ranked as one of America’s “best” by U.S. News & World Report were nearly two and half times more likely to survive the operation than those who had the same procedure done at a nonranked ...

Breast Cancer
Bladder Cancer
Gastrointestinal Cancer
Hepatobiliary Cancer
Lung Cancer
Immunotherapy

FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval

Recently, the U.S. Food and Drug Administration (FDA) announced that the agency will hold a public meeting of the Oncologic Drugs Advisory Committee on April 27 to 29 to discuss six indications granted accelerated approval that have since reported results from confirmatory trials that have not...

Gastrointestinal Cancer
Immunotherapy

Study Reports Little Benefit to Adding Pembrolizumab to Neoadjuvant Therapy for Locally Advanced Rectal Cancer

The addition of pembrolizumab to neoadjuvant chemotherapy and radiotherapy (ie, total neoadjuvant therapy) failed to improve a rectal cancer–specific surrogate for survival in patients with locally advanced disease in the phase II NRG-GI002 trial.1 As reported at the 2021 Gastrointestinal Cancers...

Gastrointestinal Cancer

Long-Term Follow-up of Adjuvant Imatinib for Localized Gastrointestinal Stromal Tumors

Final analysis of a collaborative intergroup study confirmed the efficacy of adjuvant treatment with imatinib in patients with localized gastrointestinal stromal tumor (GIST) in terms of prolonged relapse-free survival. In the high-risk subgroup, there was a trend toward a better long-term imatinib ...

Gastrointestinal Cancer

ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers

Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...

Gastrointestinal Cancer

FGFR2 Inhibitor Infigratinib Active in Chemotherapy-Refractory Cholangiocarcinoma

The novel targeted agent infigratinib (BGJ398) showed clinically meaningful activity against chemotherapy-refractory cholangiocarcinoma in patients with fibroblast growth factor receptor (FGFR2) fusions and rearrangements. The confirmed overall response rate was 23% (34% confirmed/unconfirmed), the ...

Gastrointestinal Cancer

Updated Findings Bolster the Use of Checkpoint Inhibitors in Treatment of Liver Cancer

Although optimal regimens are still being determined, checkpoint inhibition has clearly established itself in the treatment of hepatocellular carcinoma, as judged by the number of abstracts on the topic at the 2021 Gastrointestinal Cancers Symposium. The ASCO Post brings readers short summaries of ...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Addition of Andecaliximab to mFOLFOX6 in First-Line Treatment of HER2-Negative Advanced Gastric Cancer

As reported in the Journal of Clinical Oncology by Manish A. Shah, MD, and colleagues, the phase III GAMMA-1 trial showed no improvement in overall survival with the addition of andecaliximab to modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) in the first-line treatment of...

Gastrointestinal Cancer
Immunotherapy

Expert Point of View: John C. Krauss, MD

The invited discussant of the GARNET study, John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, observed that “impressive” response rates to dostarlimab were demonstrated in a “relatively...

Gastrointestinal Cancer
Immunotherapy

Anti–PD-1 Antibody Dostarlimab Active in Mismatch Repair–Deficient Gastrointestinal Tumors

Dostarlimab, a monoclonal antibody targeting PD-1, showed antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported at the 2021 Gastrointestinal Cancers Symposium by Thierry André, MD, of Sorbonne University and Saint-Antoine...

Gastrointestinal Cancer
Genomics/Genetics
Issues in Oncology
COVID-19

ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers

Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...

Immunotherapy
Gastroesophageal Cancer
Gastrointestinal Cancer
Colorectal Cancer
Bladder Cancer
Skin Cancer
Sarcoma
Hepatobiliary Cancer

FDA Pipeline: Priority Reviews for Immunotherapies in Gastric Cancers, Anal Cancer

The U.S. Food and Drug Administration (FDA) recently granted Priority Review to nivolumab as either adjuvant or first-line therapy in several types of gastric cancers, as well as to a novel PD-1 inhibitor for locally advanced or metastatic squamous cell carcinoma of the anal canal. The FDA also...

Gastrointestinal Cancer
Colorectal Cancer
Gastroesophageal Cancer

Anti–PD-1 Therapy Dostarlimab for dMMR Gastrointestinal Cancers: Safety and Efficacy Examined

Dostarlimab, a monoclonal antibody targeting PD-1, showed strong and durable antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Bemarituzumab Plus Chemotherapy Improves Outcomes in Advanced Gastric/Gastroesophageal Junction Cancer

Gastric cancer has a new target: fibroblast growth factor receptor 2b (FGFR2b). Targeting FGFR2b with bemarituzumab plus chemotherapy led to clinically meaningful and statistically significant improvements in progression-free survival, overall survival, and response rates in the randomized phase II ...

Advertisement

Advertisement

Advertisement